Familial hypercholesterolemia is a common genetic disorder with a propensity towards early onset of atherosclerotic cardiovascular disease (CVD). The main goal of therapy is to reduce the LDL cholesterol and the current treatment generally consists of statin, ezetimibe and PCSK9 inhibitors. Unfortunately, lowering LDL cholesterol may be difficult for many reasons such as the variation of response to statin therapy among the population or the high cost of some therapies (i.e., PCSK9 inhibitors). In addition to conventional therapy, additional strategies may be used. The gut microbiota has been recently considered to play a part in chronic systemic inflammation and hence in CVD. Several studies, though they are still preliminary, consider dysbiosis a risk factor for various CVDs through several mechanisms. In this review, we provide an update of the current literature about the intricate relation between the gut microbiota and the familial hypercholesterolemia.

Familial Hypercholesterolemia and Acute Coronary Syndromes: The Microbiota–Immunity Axis in the New Diagnostic and Prognostic Frontiers / Andrea Piccioni, Elena Niccolai, Gloria Rozzi, Giacomo Spaziani, Christian Zanza,Marcello Candelli, Marcello Covino, Antonio Gasbarrini, Francesco Franceschi, Amedeo Amedei. - In: PATHOGENS. - ISSN 2076-0817. - ELETTRONICO. - (2023), pp. 627-627.

Familial Hypercholesterolemia and Acute Coronary Syndromes: The Microbiota–Immunity Axis in the New Diagnostic and Prognostic Frontiers

Elena Niccolai
;
Amedeo Amedei
2023

Abstract

Familial hypercholesterolemia is a common genetic disorder with a propensity towards early onset of atherosclerotic cardiovascular disease (CVD). The main goal of therapy is to reduce the LDL cholesterol and the current treatment generally consists of statin, ezetimibe and PCSK9 inhibitors. Unfortunately, lowering LDL cholesterol may be difficult for many reasons such as the variation of response to statin therapy among the population or the high cost of some therapies (i.e., PCSK9 inhibitors). In addition to conventional therapy, additional strategies may be used. The gut microbiota has been recently considered to play a part in chronic systemic inflammation and hence in CVD. Several studies, though they are still preliminary, consider dysbiosis a risk factor for various CVDs through several mechanisms. In this review, we provide an update of the current literature about the intricate relation between the gut microbiota and the familial hypercholesterolemia.
2023
627
627
Andrea Piccioni, Elena Niccolai, Gloria Rozzi, Giacomo Spaziani, Christian Zanza,Marcello Candelli, Marcello Covino, Antonio Gasbarrini, Francesco Fra...espandi
File in questo prodotto:
File Dimensione Formato  
pathogens-12-00627-v2.pdf

accesso aperto

Tipologia: Pdf editoriale (Version of record)
Licenza: Open Access
Dimensione 305 kB
Formato Adobe PDF
305 kB Adobe PDF

I documenti in FLORE sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificatore per citare o creare un link a questa risorsa: https://hdl.handle.net/2158/1308558
Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus 3
  • ???jsp.display-item.citation.isi??? 2
social impact